|

Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI

RECRUITINGSponsored by Collegium Medicum w Bydgoszczy
Actively Recruiting
SponsorCollegium Medicum w Bydgoszczy
Started2025-11-01
Est. completion2025-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07231939

Summary

All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion. The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available. The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* all consecutive patients who underwent PCI or coronary angiography during the study period for whom the variables required for the analysis are available

Exclusion Criteria:

* unavailability of variables required for the analysis, volume
* contrast agent volume \<50 mL or \>500 mL.

Conditions5

Acute Kidney InjuryContrast-Induced Acute Kidney InjuryCoronary Artery DiseaseHeart DiseasePercutaneous Coronary Intervention

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.